CorMedix Inc. ("CorMedix") (NYSE Amex: CRMD.U), a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of cardiorenal disease, today announced that the U.S. Patent and Trademark Office has issued a patent for the use of Neutrolin® for preventing infection and clotting in hemodialysis catheters. The invention further relates to an improved composition for maintaining patency of indwelling catheters involved in central blood access. U.S. Patent No. 7,696,182 was issued to ND Partners, LLC, and expires in 2025. CorMedix holds an exclusive worldwide license with ND Partners, LLC to develop Neutrolin® for the prevention of CRBI.
“The issuance of this patent further fortifies our patent protection in the United States for Neutrolin®, and is a testament to our ongoing efforts to enhance our intellectual property portfolio for our development programs and our technology platform for the prevention of CRBI”
"The issuance of this patent further fortifies our patent protection in the United States for Neutrolin®, and is a testament to our ongoing efforts to enhance our intellectual property portfolio for our development programs and our technology platform for the prevention of CRBI," stated John C. Houghton, President and CEO of CorMedix.
Predicting mood episodes with sleep data: A breakthrough for mental health care